
The article employs measured, analytical language with the literary allusion 'one dog did not (yet) bark' that signals sophisticated commentary rather than advocacy. Framing centers on legal process and institutional competence (FDA role), presenting the absence of an FDA filing as a notable gap in Supreme Court deliberation. The tone is observational about the regulatory apparatus rather than charged toward either abortion access or restrictions.
Primary voices: media outlet
Framing will likely shift substantially once the Supreme Court issues its decision, which will recontextualize the significance of the missing FDA filing.
It appears the Supreme Court will decide the fate of telemedicine prescriptions for mifepristone without the benefit of an FDA filing.
Full article not available — click below to read at the source.
Comments
No comments yet. Be the first.
Sign in to leave a comment.